Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 363540, 7 pages
http://dx.doi.org/10.1155/2014/363540
Research Article

MYD88 L265P Mutations Are Correlated with 6q Deletion in Korean Patients with Waldenström Macroglobulinemia

1Department of Laboratory Medicine, Seoul National University College of Medicine, 101 Daehangno, Jongno-gu, Seoul 110-744, Republic of Korea
2Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
3Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
4Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan
5Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

Received 21 February 2014; Revised 14 April 2014; Accepted 14 April 2014; Published 7 May 2014

Academic Editor: Wee-Joo Chng

Copyright © 2014 Jung-Ah Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Vijay and M. A. Gertz, “Waldenström macroglobulinemia,” Blood, vol. 109, no. 12, pp. 5096–5103, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. R. G. Owen, S. P. Treon, A. Al-Katib et al., “Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia,” Seminars in Oncology, vol. 30, no. 2, pp. 110–115, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. S. H. Swerdlow, E. Campo, N. L. Harris et al., Eds., World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, 4th edition, 2008.
  4. S. P. Treon, P. Morel, V. Leblond, and J.-P. Fermand, “Report of the Third International Workshop on Waldenstrom's macroglobulinemia,” Clinical Lymphoma, vol. 5, no. 4, pp. 215–216, 2005. View at Google Scholar · View at Scopus
  5. F. D. Groves, L. B. Travis, S. S. Devesa, L. A. Ries, and J. F. Fraumeni Jr., “Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988–1994,” Cancer, vol. 82, no. 6, pp. 1078–1081, 1998. View at Google Scholar
  6. Y. H. Ko, C. W. Kim, C. S. Park et al., “REAL classification of malignant lymphomas in the Republic of Korea,” Cancer, vol. 83, no. 4, pp. 806–812, 1998. View at Google Scholar
  7. S. P. Treon, Z. R. Hunter, A. Aggarwal et al., “Characterization of familial Waldenstrom's macroglobulinemia,” Annals of Oncology, vol. 17, no. 3, pp. 488–494, 2006. View at Google Scholar
  8. S. P. Treon, L. Xu, G. Yang et al., “MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia,” The New England Journal of Medicine, vol. 367, no. 9, pp. 826–833, 2012. View at Publisher · View at Google Scholar
  9. N. Gachard, M. Parrens, I. Soubeyran et al., “IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas,” Leukemia, vol. 27, no. 1, pp. 183–189, 2013. View at Publisher · View at Google Scholar
  10. C. Jimenez, E. Sebastian, M. C. Chillon et al., “MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia,” Leukemia, vol. 27, no. 8, pp. 1722–1728, 2013. View at Publisher · View at Google Scholar
  11. S. Poulain, C. Roumier, A. Decambron et al., “MYD88 L265P mutation in Waldenstrom macroglobulinemia,” Blood, vol. 121, no. 22, pp. 4504–4511, 2013. View at Publisher · View at Google Scholar
  12. S. P. Treon and Z. R. Hunter, “A new era for Waldenstrom macroglobulinemia: MYD88 L265P,” Blood, vol. 121, no. 22, pp. 4434–4436, 2013. View at Publisher · View at Google Scholar
  13. M. Varettoni, L. Arcaini, S. Zibellini et al., “Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms,” Blood, vol. 121, no. 13, pp. 2522–2528, 2013. View at Publisher · View at Google Scholar
  14. L. Xu, Z. R. Hunter, G. Yang et al., “MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction,” Blood, vol. 121, no. 11, pp. 2051–2058, 2013. View at Publisher · View at Google Scholar
  15. G. Yang, Y. Zhou, X. Liu et al., “A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia,” Blood, vol. 122, no. 7, pp. 1222–1232, 2013. View at Publisher · View at Google Scholar
  16. M. L. Slovak and L. J. Campbell, “International System of Human Cytogenetic Nomenclature,” ISCN, S Karger AG, Basel, Switzerland, 2005.
  17. M. L. Slovak and L. J. Campbell, “International System of Human Cytogenetic Nomenclature,” ISCN, S Karger AG, Basel, Switzerland, 2009.
  18. L. Xu, Z. R. Hunter, G. Yang et al., “MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction,” Blood, vol. 121, no. 11, pp. 2051–2058, 2013. View at Google Scholar
  19. M. Varettoni, L. Arcaini, S. Zibellini et al., “Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms,” Blood., vol. 121, no. 13, pp. 2522–2528, 2013. View at Google Scholar
  20. R. F. J. Schop, S. A. Van Wier, R. Xu et al., “6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance,” Cancer Genetics and Cytogenetics, vol. 169, no. 2, pp. 150–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Terré, F. Nguyen-Khac, C. Barin et al., “Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases,” Leukemia, vol. 20, no. 9, pp. 1634–1636, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. R. F. J. Schop, W. Michael Kuehl, S. A. Van Wier et al., “Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions,” Blood, vol. 100, no. 8, pp. 2996–3001, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Chang, X. Qi, W. Xu, J. C. Reader, and Y. Ning, “Analysis of 6q deletion in Waldenstrom macroglobulinemia,” European Journal of Haematology, vol. 79, no. 3, pp. 244–247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S.-M. Bang, J.-W. Seo, K. U. Park et al., “Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia,” Cancer Genetics and Cytogenetics, vol. 197, no. 2, pp. 117–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. N. C. Gutiérrez, E. M. Ocio, J. de las Rivas et al., “Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals,” Leukemia, vol. 21, no. 3, pp. 541–549, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Poulain, E. Braggio, C. Roumier et al., “High-throughput genomic analysis in Waldenström's macroglobulinemia,” Clinical Lymphoma, Myeloma and Leukemia, vol. 11, no. 1, pp. 106–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Alexander Turner Jr., D. H. Mack, and M. M. Davis, “Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells,” Cell, vol. 77, no. 2, pp. 297–306, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. K. L. Calame, K.-I. Lin, and C. Tunyaplin, “Regulatory mechanisms that determine the development and function of plasma cells,” Annual Review of Immunology, vol. 21, pp. 205–230, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. A. L. Shaffer, M. Shapiro-Shelef, N. N. Iwakoshi et al., “XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation,” Immunity, vol. 21, no. 1, pp. 81–93, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. S. G. Hymowitz and I. E. Wertz, “A20: from ubiquitin editing to tumour suppression,” Nature Reviews Cancer, vol. 10, no. 5, pp. 332–340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Ma and B. A. Malynn, “A20: linking a complex regulator of ubiquitylation to immunity and human disease,” Nature Reviews Immunology, vol. 12, no. 11, pp. 774–785, 2012. View at Publisher · View at Google Scholar
  32. M. Muzio, J. Ni, P. Feng, and V. M. Dixit, “IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling,” Science, vol. 278, no. 5343, pp. 1612–1615, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Wesche, W. J. Henzel, W. Shillinglaw, S. Li, and Z. Cao, “MyD88: an adapter that recruits IRAK to the IL-1 receptor complex,” Immunity, vol. 7, no. 6, pp. 837–847, 1997. View at Publisher · View at Google Scholar · View at Scopus